Susquehanna International Group, LLP Merus N.V. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$47.19 - $58.84 $410,553 - $511,908	-8,700 Reduced 7.76%	103,400 $5.17 Million
Q2 2024 Aug 15, 2024	BUY	$39.81 - $60.2 $1.33 Million - $2 Million	33,300 Added 42.26%	112,100 $6.63 Million
Q1 2024 May 07, 2024	BUY	$28.03 - $51.82 $1.7 Million - $3.15 Million	60,700 Added 335.36%	78,800 $3.55 Million
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $214,642 - $306,662	-10,700 Reduced 37.15%	18,100 $497,000
Q3 2023 Nov 14, 2023	BUY	$20.13 - $27.29 $402,600 - $545,800	20,000 Added 227.27%	28,800 $679,000
Q2 2023 Aug 11, 2023	BUY	$18.33 - $27.18 $161,303 - $239,184	8,800 New	8,800 $231,000
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $296,376 - $459,987	15,900 New	15,900 $318,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.